Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelofibrosis and Chronic Myelomonocytic Leukemia

NCT05233618 is registered in ClinicalTrials.gov with Karen Ballen, MD as lead sponsor.

NCT NCT05233618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05233618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelofibrosis and Chronic Myelomonocytic Leukemia
Lead sponsor
Karen Ballen, MD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 13, 2022
Completion date
December 1, 2026
Enrollment
44 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic myelomonocytic leukemia, myelofibrosis